NASDAQ · NVCT
Healthcare · Biotechnology
$23.56
Up+$0.49 (+2.06%)
Updated Aug 24, 2026, 7:13 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NVCT closed at $23.56 after 20 trading sessions, up 20.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $23.59 | $23.9299 | $22.83 | $23.56 | 196.98K |
| Aug 20, 2026 | $22.98 | $23.99 | $22.36 | $23.35 | 230.01K |
| Aug 19, 2026 | $21.44 | $23.74 | $21.00 | $23.33 | 362.93K |
| Aug 18, 2026 | $19.13 | $20.91 | $19.06 | $20.91 | 217.87K |
| Aug 17, 2026 | $18.85 | $19.32 | $18.51 | $19.08 | 102.6K |
| Aug 14, 2026 | $20.30 | $20.30 | $18.865 | $18.96 | 106.66K |
| Aug 13, 2026 | $19.78 | $20.008 | $19.05 | $19.23 | 144.24K |
| Aug 12, 2026 | $19.68 | $19.74 | $19.34 | $19.54 | 78.9K |
| Aug 11, 2026 | $19.09 | $19.75 | $18.62 | $19.41 | 166.24K |
| Aug 10, 2026 | $18.68 | $18.90 | $18.30 | $18.875 | 137.15K |
| Aug 7, 2026 | $19.16 | $19.46 | $18.31 | $18.95 | 171.97K |
| Aug 6, 2026 | $19.22 | $19.99 | $18.40 | $18.83 | 210.55K |
| Aug 5, 2026 | $21.09 | $21.09 | $19.15 | $19.26 | 220.13K |
| Aug 4, 2026 | $19.26 | $21.12 | $17.89 | $20.10 | 592.17K |
| Aug 3, 2026 | $21.57 | $22.87 | $21.50 | $21.60 | 204.62K |
| Jul 31, 2026 | $23.12 | $23.12 | $21.21 | $21.52 | 158.83K |
| Jul 30, 2026 | $21.09 | $22.945 | $21.0101 | $22.76 | 300K |
| Jul 29, 2026 | $19.95 | $21.29 | $19.75 | $20.69 | 287.57K |
| Jul 28, 2026 | $19.85 | $20.00 | $19.00 | $19.82 | 195.51K |
| Jul 27, 2026 | $19.37 | $20.00 | $19.01 | $19.54 | 146.61K |
The latest Smart Investors Daily articles mentioning NVCT.
NVCT research
Company profile and research snapshot.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | Roth Capital | Buy | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 30, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 30, 2026
Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate, hiring of additional personnel, capital
Benzinga · Jun 29, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced
Benzinga · Feb 13, 2026
-SEC Filing
Yahoo · Feb 11, 2026
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “20
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVCT.
